Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States.

Abstract:

BACKGROUND:As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS in the United States obtained early in the COVID-19 pandemic, the current study aimed to: (1) assess willingness to get a COVID-19 vaccine when available; (2) determine demographic, MS, and psychosocial correlates of vaccine willingness; and (3) measure where people with MS get their COVID-19 information and their perceived trustworthiness of such sources, which may influence COVID-19 vaccine willingness. METHODS:Adults with MS (N = 486) living in the United States completed a cross-sectional online survey (between 10 April 2020 and 06 May 2020) about their willingness to receive a COVID-19 vaccination once available. Participants also completed measures to describe the sample and to assess factors potentially related to vaccine willingness, including demographics, MS-specific variables, psychological measures, COVID-19 information sources, and perceived trustworthiness of their information sources. RESULTS:Approximately two-thirds of the participants (66.0%) reported a willingness to obtain a future COVID-19 vaccine, whereas 15.4%of the sample was unwilling. Greater willingness to receive the vaccine was associated with having a higher level of education and holding a higher perception of one's risk of catching COVID-19. Participants reported accessing COVID-19 information from many different sources. Approximately a third (31.6%) of the sample reported getting their information from healthcare providers. Healthcare providers and the National MS Society had the highest perceived trustworthiness for COVID-19 information. The perceived trustworthiness of information sources was highly associated with vaccine willingness. CONCLUSION:Early in the pandemic, willingness to get a COVID-19 vaccine was not universal in this large sample or people living with MS. Vaccine willingness was associated with a few variables including education level, perceived risk for COVID-19 infection, and trust in COVID-19 information sources. These results have important implications for guiding healthcare providers and the MS community as COVID-19 vaccines become widely available.

authors

Ehde DM,Roberts MK,Herring TE,Alschuler KN

doi

10.1016/j.msard.2021.102788

subject

Has Abstract

pub_date

2021-01-22 00:00:00

pages

102788

eissn

2211-0348

issn

2211-0356

pii

S2211-0348(21)00054-7

journal_volume

49

pub_type

杂志文章
  • Targeting macrophages by an aza-anthrapyrazole to ameliorate experimental autoimmune encephalomyelitis.

    abstract:BACKGROUND:Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease in the central nerve system, in which both innate and adaptive immune cells are involved. BBR3378, an aza-anthrapyrazole prevents experimental autoimmune encephalomyelitis (EAE), an inflammatory condition similar to MS, by antagonizing T...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102190

    authors: Lin B,Launder D,Bailey DY,Assifuah FK,Miller OA,Conti HR,Du J,Koffman BM

    更新日期:2020-08-01 00:00:00

  • Impaired central drive to plantarflexors and minimal ankle proprioceptive deficit in people with multiple sclerosis.

    abstract:BACKGROUND:A common and disruptive symptom of multiple sclerosis is difficulty in walking. Deficits in ankle proprioception and in plantarflexor muscle function may contribute to these mobility issues. In this study, ankle proprioceptive ability and plantarflexor performance of people with multiple sclerosis (PwMS) wer...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102584

    authors: Djajadikarta ZJ,Dongés SC,Brooks J,Kennedy DS,Gandevia SC,Taylor JL

    更新日期:2020-11-01 00:00:00

  • Five year iron changes in relapsing-remitting multiple sclerosis deep gray matter compared to healthy controls.

    abstract:BACKGROUND:Relapsing-Remitting MS (RRMS) Deep Grey Matter (DGM) 5 year changes were examined using MRI measures of volume, transverse relaxation rate (R2*) and quantitative magnetic susceptibility (QS). By applying Discriminative Analysis of Regional Evolution (DARE), R2* and QS changes from iron and non-iron sources w...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.05.028

    authors: Elkady AM,Cobzas D,Sun H,Seres P,Blevins G,Wilman AH

    更新日期:2019-08-01 00:00:00

  • A temporal analysis of bilateral gait coordination in people with multiple sclerosis.

    abstract:BACKGROUND:Gait performance often dictates an individual's ability to navigate the dynamic environments of everyday living. With each stride, the lower extremities move through phases of stance, swing, and double support. Coordinating these motions with high accuracy and consistency is imperative to constraining the ce...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102445

    authors: Richmond SB,Swanson CW,Peterson DS,Fling BW

    更新日期:2020-10-01 00:00:00

  • Views on disclosing mistreatment: A focus group study of differences between people with MS and their caregivers.

    abstract:UNLABELLED:Both female and male persons with MS are at increased risk for various forms of physical, sexual, and disability-specific abuse. An ongoing study revealed a subset of respondents in which the caregiver acknowledged mistreatment of the person with MS, but that person either denied or minimized mistreatment M...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2012.09.006

    authors: Shapiro J,Wiglesworth A,Morrison EH

    更新日期:2013-04-01 00:00:00

  • To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis.

    abstract:BACKGROUND:The frequency and long-term prognosis of relapsing multiple sclerosis (RMS) never receiving disease-modifying treatment (DMT) is unclear. METHODS:We included 1186 RMS patients with a mean of 17.4 years follow-up and divided them into patients treated with any DMT (DMT) and patients untreated by shared (USD)...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.101908

    authors: Bsteh G,Hegen H,Dosser C,Auer M,Berek K,Wurth S,Zinganell A,Di Pauli F,Deisenhammer F,Berger T

    更新日期:2019-12-23 00:00:00

  • Peak width of skeletonized mean diffusivity (PSMD) as marker of widespread white matter tissue damage in multiple sclerosis.

    abstract:BACKGROUND:Peak width of skeletonized mean diffusivity (PSMD) is a novel and fully automated, MRI biomarker, which has shown clinical relevance in cerebral small vessel diseases (SVD). We aimed here to assess PSMD levels across the brain of patients with multiple sclerosis (MS), in comparison to normal controls (NC) an...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.11.011

    authors: Vinciguerra C,Giorgio A,Zhang J,Di Donato I,Stromillo ML,Tappa Brocci R,Federico A,Dotti MT,De Stefano N

    更新日期:2019-01-01 00:00:00

  • Rituximab-induced serum sickness in multiple sclerosis patients.

    abstract::Rituximab is a chimeric anti-CD20 monoclonal antibody that is an effective therapy for multiple sclerosis. Rituximab has been associated with the development of serum sickness (type III hypersensitivity) characterized by arthralgia, fever, and rash during the treatment of other conditions, such as rheumatoid arthritis...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.101402

    authors: Wolf AB,Ryerson LZ,Pandey K,McGettigan BM,Vollmer T,Corboy JR,Alvarez E

    更新日期:2019-11-01 00:00:00

  • Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with multiple sclerosis: A meta-analysis.

    abstract:BACKGROUND:Multiple reports have described the proportion of Th17 cells in peripheral blood and serum levels of Th17-related cytokines in patients with multiple sclerosis (MS). To clarify the status of Th17 cells and Th17-related cytokines in MS patients, we did a meta-analysis of the results published previously to as...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.msard.2017.09.003

    authors: Li YF,Zhang SX,Ma XW,Xue YL,Gao C,Li XY

    更新日期:2017-11-01 00:00:00

  • Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment.

    abstract::Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rat...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2015.04.005

    authors: Barroso B,Miquel M,Marasescu R,Demasles S,Krim E,Bonnan M

    更新日期:2015-07-01 00:00:00

  • Aphasic status epilepticus preceding tumefactive left hemisphere lesion in anti-MOG antibody associated disease.

    abstract:INTRODUCTION:Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies have recently been associated with epilepsy with FLAIR hyperintense cortical lesions on MRI. Association between anti-MOG antibodies and epilepsy without detectable structural brain lesion on MRI is unknown. CASE REPORT:A 48-year-old right-handed m...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.10.012

    authors: Katsuse K,Kurihara M,Sugiyama Y,Kodama S,Takahashi M,Momose T,Yumoto M,Kaneko K,Takahashi T,Kubota A,Hayashi T,Toda T

    更新日期:2019-01-01 00:00:00

  • CADASIL as Multiple Sclerosis Mimic: A 48-year-old man with severe leukoencephalopathy and spinal cord involvement.

    abstract::Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a common cause of inherited stroke in young adults. CADASIL causes extensive white matter T2 hyperintensities at brain MRI, in particular involving anterior-temporal lobes and external capsules; usually, there is no...

    journal_title:Multiple sclerosis and related disorders

    pub_type:

    doi:10.1016/j.msard.2020.102014

    authors: Motolese F,Rossi M,Gangemi E,Bersano A,Scelzo E,Di Lazzaro V,Capone F

    更新日期:2020-06-01 00:00:00

  • 2017 McDonald criteria for multiple sclerosis: Earlier diagnosis with reduced specificity?

    abstract:BACKGROUND:McDonald criteria for multiple sclerosis (MS) diagnosis were revised in 2017. OBJECTIVE:Aim of our study was to evaluate and compare the sensitivity and specificity of 2017 and 2010 McDonald criteria in patients presenting with an initial demyelinating event (IDE). METHODS:We retrospectively identified pat...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.01.008

    authors: Gobbin F,Zanoni M,Marangi A,Orlandi R,Crestani L,Benedetti MD,Gajofatto A

    更新日期:2019-04-01 00:00:00

  • Effect of fingolimod (FTY720) on choroidal thickness in patients with multiple sclerosis.

    abstract:OBJECTIVE:Using spectral domain optical coherence tomography (SD-OCT), to compare the choroidal thickness in a healthy population (group 1), with newly diagnosed multiple sclerosis (MS) patients (group 2), with MS patients who underwent β-interferon monotherapy (group 3) and MS patients who underwent fingolimod therapy...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.03.005

    authors: Kal A,Oğuz Ulusoy M,Horasanlı B,Cezairlioğlu Ş,Kal Ö

    更新日期:2017-05-01 00:00:00

  • COVID-19 in ocrelizumab-treated people with multiple sclerosis.

    abstract:BACKGROUND:There are limited data on the impact of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on people with multiple sclerosis (MS). OBJECTIVE:To better understand SARS-CoV-2 infection in ocrelizumab-treated people with MS. METHODS:Internal Roche/Ge...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102725

    authors: Hughes R,Whitley L,Fitovski K,Schneble HM,Muros E,Sauter A,Craveiro L,Dillon P,Bonati U,Jessop N,Pedotti R,Koendgen H

    更新日期:2020-12-30 00:00:00

  • Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report.

    abstract::Thrombotic microangiopathy (TMA) is a rare but increasingly recognized complication of interferon-beta therapy, which can be associated with serious sequelae. We report on a 53-year-old woman with a longstanding history of relapsing-remitting multiple sclerosis, who developed TMA after 15 years of high-dose treatment ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.09.002

    authors: Gerischer LM,Siebert E,Janke O,Jungehuelsing GJ,Ruprecht K

    更新日期:2016-11-01 00:00:00

  • Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records.

    abstract:BACKGROUND:Little is known about the factors associated with the selection of Disease Modifying Agents (DMA) for the management of Multiple Sclerosis (MS) since the introduction of oral DMAs in 2010. OBJECTIVES:To examine the factors associated with initiation of oral DMAs in patients with MS using data from electroni...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102334

    authors: Earla JR,Hutton GJ,Thornton JD,Aparasu RR

    更新日期:2020-10-01 00:00:00

  • Could Sars-Cov2 affect MS progression?

    abstract::A long-term neurologic sequela arising from COVID-19 infection in multiple sclerosis (MS) patients could be related both to the increase of cytokines and the activation of NLRP3 inflammasome by the Sars-CoV2. These two mechanisms may cause a worsening of MS several months after the resolution of the infection. ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.102540

    authors: Di Stadio A,Romani L,Bernitsas E

    更新日期:2020-11-01 00:00:00

  • Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients.

    abstract:BACKGROUND:The 2015 International Panel for neuromyelitis optica (NMO) spectrum disorders (NMOSD) diagnosis (IPND) criteria was recently proposed. However, because there are no studies evaluating application of the IPND criteria in Latin American populations, we aimed to assess whether these new criteria improve the di...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.01.001

    authors: Carnero Contentti E,Soto de Castillo I,Daccach Marques V,López PA,Antunes Barreira A,Armas E,de Aquino Cruz C,Rubstein A,Lavigne Moreira C,Molina OM,Soto A,Tkachuk V

    更新日期:2018-02-01 00:00:00

  • Hypothesis: Multiple sclerosis is caused by three-hits, strictly in order, in genetically susceptible persons.

    abstract::Multiple Sclerosis is a chronic, progressive and debilitating neurological disease which, despite extensive study for over 100 years, remains of enigmatic aetiology. Drawn from the epidemiological evidence, there exists a consensus that there are environmental (possibly infectious) factors that contribute to disease p...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.06.014

    authors: Kearns PKA,Casey HA,Leach JP

    更新日期:2018-08-01 00:00:00

  • Extratemporal herpes encephalitis during natalizumab treatment: A case report.

    abstract::Herpes simplex virus encephalitis (HSE) is a rare but often fatal disease if left untreated. MRI typically shows the characteristic findings of medial temporal lobe and insular involvement, while diagnosis in confirmed by CSF PCR. In immunocompromised state, HSE may have atypical clinical and radiological features. We...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.10.002

    authors: Haggiag S,Prosperini L,Galgani S,Pozzilli C,Pinnetti C

    更新日期:2016-11-01 00:00:00

  • Visual pathway involvement in multiple sclerosis: Look straight in the eyes.

    abstract::Visual symptoms are a common clinical manifestation of multiple sclerosis (MS) and are frequently due to acute optic neuritis (ON). However, the entire visual pathway can be involved throughout the disease course. We describe the case of a young MS patient who experienced visual symptoms that were eventually found to ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.08.008

    authors: Gaetani L,Iaccheri B,Cerquaglia A,Gentili L,Fiore T,Di Gregorio M,Mancini A,Calabresi P,Cagini C,Sarchielli P,Di Filippo M

    更新日期:2017-10-01 00:00:00

  • Are fatigue scales the same? A content comparison using the International Classification of Functioning, Disability and Health.

    abstract:BACKGROUND:Fatigue is a common impairment in a wide range of disorders. Numerous fatigue scales have been designed in an attempt to quantify this impairment without any clear distinction between them. The International Classification of Functioning, Disability and Health (ICF) is a useful tool for content comparison of...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102596

    authors: Alghwiri AA,Almhdawi KA,Marchetti G

    更新日期:2020-11-01 00:00:00

  • A review of the ethics of the use of placebo in clinical trials for relapsing-remitting multiple sclerosis therapeutics.

    abstract::Randomized placebo-controlled clinical trials have been considered the most rigorous method of evaluating the efficacy of novel treatment interventions. The first effective disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) were approved in the 1990s after a number of pivotal placebo-...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2016.03.019

    authors: Solomon AJ,Bernat JL

    更新日期:2016-05-01 00:00:00

  • A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.

    abstract::Fingolimod, taken orally once per day, is approved for the treatment of relapsing-remitting multiple sclerosis (MS). It should be stopped at least two months before conception as it is not considered safe during pregnancy or when breast feeding. In vitro and animal studies have found a possibly increased risk of conge...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.02.015

    authors: Navardi S,Sahraian MA

    更新日期:2018-04-01 00:00:00

  • The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis.

    abstract:INTRODUCTION:Some studies have indicated the importance of considering smoking, vitamin D deficiency and obesity as negative prognostic factors for clinical and MRI outcomes in multiple sclerosis (MS). This study aimed to evaluate the possible effects of these modifiable risk factors on brain MRI lesion burden of patie...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.101886

    authors: Lorefice L,Destro F,Fenu G,Mallus M,Gessa I,Sechi V,Barracciu MA,Frau J,Coghe G,Carmagnini D,Marrosu MG,Saba L,Cocco E

    更新日期:2019-12-09 00:00:00

  • Forkhead box C1 gene variant causing glaucoma and small vessel angiopathy can mimic multiple sclerosis.

    abstract::A 34-year old Caucasian female was initially diagnosed with multiple small-vessel strokes at age 20 years which were etiologically classified as secondary to anti-phospholipid antibody syndrome (APS) although she had no history or laboratory data to suggest APS. Based on her MRI of brain findings, one of her neurologi...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.04.004

    authors: Avasarala JR,Jones JR,Rogers CR

    更新日期:2018-05-01 00:00:00

  • Post herpes zoster infection neuromyelitis optica spectrum disorder.

    abstract::Neuromyelitis optica is a severe autoimmune demyelinating disease; however, the trigger for autoimmunity in an individual patient is unclear. Here, we report the case of a 48 year old female presenting with longitudinally extensive transverse myelitis in the cervical region of the spinal cord two weeks post herpes zos...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.09.022

    authors: Mathew T,Thomas K,Shivde S,Venkatesh S,Rockey SM

    更新日期:2017-11-01 00:00:00

  • Does natalizumab treatment increase the risk of herpes simplex encephalitis in multiple sclerosis? Case and discussion.

    abstract::This report presents the 4th documented case worldwide of herpes simplex encephalitis in multiple sclerosis (MS) patients treated with natalizumab and the first case in the UK. Natalizumab is licensed for relapsing remitting multiple sclerosis in patients with high disease activity despite treatment with interferon-be...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2013.02.006

    authors: Sharma K,Ballham SA,Inglis KE,Renowden S,Cottrell DA

    更新日期:2013-10-01 00:00:00

  • Clinical decision-making in multiple sclerosis: Challenges reported internationally with emerging treatment complexity.

    abstract:INTRODUCTION:The introduction of several new disease-modifying therapies (DMTs) to the field of Multiple Sclerosis (MS) treatment requires that MS healthcare providers have a comprehensive understanding of the implications of each new treatment option in order to select the treatment that best suits their patient. An i...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2015.05.008

    authors: Ng P,Murray S,Hayes SM

    更新日期:2015-07-01 00:00:00